MCID: TXC002
MIFTS: 53

Toxic Encephalopathy

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Toxic Encephalopathy

MalaCards integrated aliases for Toxic Encephalopathy:

Name: Toxic Encephalopathy 12 52 15 17 32
Neurotoxicity Syndromes 74 52 43
Neurotoxicity 12 53 15
Neurotoxicity Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3602
MeSH 43 D020258
NCIt 49 C27961
SNOMED-CT 67 19466003
ICD10 32 G92
UMLS 71 C0235032

Summaries for Toxic Encephalopathy

NINDS : 53 Neurotoxicity occurs when the exposure to natural or manmade toxic substances (neurotoxicants) alters the normal activity of the nervous system. This can eventually disrupt or even kill neurons, key cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from exposure to substances used in chemotherapy, radiation treatment, drug therapies, and organ transplants, as well as exposure to heavy metals such as lead and mercury, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness; loss of memory, vision, and/or intellect; headache; cognitive and behavioral problems; and sexual dysfunction. Individuals with certain disorders may be especially vulnerable to neurotoxicants.

MalaCards based summary : Toxic Encephalopathy, also known as neurotoxicity syndromes, is related to alzheimer disease and alzheimer disease 2. An important gene associated with Toxic Encephalopathy is HMOX1 (Heme Oxygenase 1), and among its related pathways/superpathways are MAPK signaling pathway and Parkinson disease. The drugs Dexmedetomidine and Cycloserine have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A nervous system disease that results from exposure to neurotoxicants and is characterized by an altered mental status, memory loss, and visual problems.

Wikipedia : 74 Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an... more...

Related Diseases for Toxic Encephalopathy

Diseases related to Toxic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1028)
# Related Disease Score Top Affiliating Genes
1 alzheimer disease 33.0 TNF TH SNCA SLC6A3 SERPINA3 PSEN1
2 alzheimer disease 2 32.8 SERPINA3 PSEN1 APP
3 neuroblastoma 31.9 TNF TH SNCA PSEN1 NGF IL1B
4 prion disease 31.7 SNCA SERPINA3 PSEN1 MIR9-1 IL1B H2AC18
5 huntington disease 31.6 TH SNCA SLC6A3 PSEN1 NGF GRIN2B
6 adrenal gland pheochromocytoma 31.6 NGF BDNF
7 scrapie 31.6 SNCA SERPINA3 MIR9-1 APP
8 fetal alcohol syndrome 31.5 MIR9-1 H2AC18 GRIN2B CASP3 BDNF
9 cerebral artery occlusion 31.5 TNF IL1B BDNF
10 amyotrophic lateral sclerosis 1 31.4 TNF TH SNCA SLC6A3 SERPINA3 PSEN1
11 spinal cord injury 31.4 TNF CASP3 BDNF
12 parkinson disease, late-onset 31.3 TH SNCA SLC6A3 SERPINA3 PSEN1 NGF
13 fetal alcohol spectrum disorder 31.3 MIR9-1 H2AC18 GRIN2B CASP3 BDNF
14 sensory peripheral neuropathy 31.3 NGF BDNF ABCB1
15 myeloma, multiple 31.2 TNF SERPINA3 MIR9-1 IL1B H2AC18 CASP3
16 amnestic disorder 31.2 PSEN1 GRIN2B BDNF APP
17 amyloidosis 31.2 TNF SNCA SERPINA3 PSEN1 IL1B APP
18 motor neuron disease 31.2 TNF SNCA MIR9-1 H2AC18 GSTM1 BDNF
19 intracranial hypertension 31.2 TNF SERPINA3 IL1B
20 mood disorder 31.2 TH SLC6A3 MIR9-1 H2AC18 BDNF
21 alcohol dependence 31.2 TNF TH SNCA SLC6A3 NGF IL1B
22 neonatal jaundice 31.1 TNF IL1B HMOX1 GSTM1
23 constipation 31.1 TNF TH SNCA H2AC18 BDNF
24 attention deficit-hyperactivity disorder 31.1 TH SNCA SLC6A3 NGF GRIN2B BDNF
25 substance abuse 31.1 SLC6A3 SERPINA3 H2AC18 BDNF
26 wernicke-korsakoff syndrome 31.1 SERPINA3 NGF BDNF
27 autosomal dominant cerebellar ataxia 31.1 SNCA SERPINA3 MIR9-1 H2AC18 APP
28 neuritis 31.0 TNF IL1B BDNF
29 optic nerve disease 31.0 TNF SNCA SERPINA3 NGF IL1B BDNF
30 temporal lobe epilepsy 31.0 IL1B GRIN2B BDNF ABCB1
31 cerebral amyloid angiopathy, cst3-related 31.0 SNCA SERPINA3 PSEN1 APP
32 stroke, ischemic 31.0 TNF TH SERPINA3 PSEN1 IL1B CASP3
33 nervous system disease 30.9 TNF SNCA SERPINA3 MIR9-1 IL1B H2AC18
34 leukoencephalopathy, hereditary diffuse, with spheroids 30.9 SNCA APP AIF1
35 sleep disorder 30.9 TNF TH SNCA SLC6A3 IL1B BDNF
36 bacterial infectious disease 30.9 TNF SERPINA3 IL1B H2AC18
37 multiple system atrophy 1 30.9 TH SNCA SLC6A3 SERPINA3
38 creutzfeldt-jakob disease 30.9 SNCA SLC6A3 SERPINA3 NGF CASP3 BDNF
39 charcot-marie-tooth disease 30.9 SNCA NGF H2AC18 BDNF APP ABCB1
40 status epilepticus 30.9 GRIN2B CASP3 BDNF ABCB1
41 autism 30.9 TNF TH SLC6A3 NGF IL1B GSTM1
42 alcohol use disorder 30.8 SLC6A3 H2AC18 GRIN2B BDNF
43 mental depression 30.8 TNF SLC6A3 SERPINA3 IL1B H2AC18 GRIN2B
44 fatal familial insomnia 30.8 SNCA SERPINA3 APP
45 major depressive disorder 30.8 TNF SLC6A3 NGF IL1B GRIN2B BDNF
46 cerebrovascular disease 30.8 TNF SERPINA3 GSTM1 APP
47 psychotic disorder 30.8 TH SLC6A3 SERPINA3 PSEN1 MIR9-1 H2AC18
48 retinal ischemia 30.8 TNF IL1B HMOX1 CASP3 BDNF AIF1
49 leukemia, acute myeloid 30.8 TNF SERPINA3 MIR9-1 IL1B H2AC18 CASP3
50 polyneuropathy 30.8 TNF NGF IL1B AIF1

Graphical network of the top 20 diseases related to Toxic Encephalopathy:



Diseases related to Toxic Encephalopathy

Symptoms & Phenotypes for Toxic Encephalopathy

MGI Mouse Phenotypes related to Toxic Encephalopathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 ABCB1 ABCG2 APP BDNF CASP3 GRIN2B
2 homeostasis/metabolism MP:0005376 10.3 ABCB1 ABCG2 AIF1 APP BDNF CASP3
3 growth/size/body region MP:0005378 10.22 ABCB1 APP BDNF CASP3 GRIN2B HMOX1
4 cardiovascular system MP:0005385 10.17 ABCB1 AIF1 APP CASP3 HMOX1 IL1B
5 immune system MP:0005387 10.06 ABCB1 ABCG2 AIF1 APP CASP3 HMOX1
6 integument MP:0010771 10.03 ABCG2 APP BDNF CASP3 IL1B NGF
7 nervous system MP:0003631 10 ABCB1 ABCG2 AIF1 APP BDNF CASP3
8 no phenotypic analysis MP:0003012 9.61 ABCB1 APP BDNF CASP3 GRIN2B NGF
9 taste/olfaction MP:0005394 8.92 BDNF CASP3 SLC6A3 SNCA

Drugs & Therapeutics for Toxic Encephalopathy

Drugs for Toxic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 486)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
2
Cycloserine Approved Phase 4 68-41-7 401 6234
3
Nalbuphine Approved Phase 4 20594-83-6 5311304 5360630
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
7
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
10
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
11
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
12
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
13
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
14
Levetiracetam Approved Phase 4 102767-28-2 441341
15
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
16
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
17
Lacosamide Approved Phase 4 175481-36-4, 860352-01-8 219078
18
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
19
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
20
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
21
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
22
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
23
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
24
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
25
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
26
Cobicistat Approved Phase 4 1004316-88-4
27
Dolutegravir Approved Phase 4 1051375-16-6 54726191
28
Sodium citrate Approved, Investigational Phase 4 68-04-2
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
30
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
31
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
32
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
33
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
34 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
35
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
36
Abatacept Approved Phase 4 332348-12-6 10237
37
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
38
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
39
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
40
Racepinephrine Approved Phase 4 329-65-7 838
41
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
42
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 43805 6857599 5310940 9887054
43
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
44
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
45
Bevacizumab Approved, Investigational Phase 4 216974-75-3
46
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
47
Mycophenolic acid Approved Phase 4 24280-93-1 446541
48
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
49
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
50
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054

Interventional clinical trials:

(show top 50) (show all 491)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
3 Impact of Pretreatment With Omega 3 Enriched Lipid Emulsion on Early Neurological Complications After Living Donor Liver Transplantation. A Randomized Controlled Trial> Unknown status NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
4 Remifentanil-dexmedetomidine Anesthesia as an Alternative Anesthetic for Elective Pediatric Surgery: a Pilot Study. Unknown status NCT02799589 Phase 4 Remifentanil;Dexmedetomidine;Ropivacaine
5 The Optimal Dose Of Dexamethasone To Be Used As An Adjuvant To Low Volume Bupivacaine Ultrasound Guided Supraclavicular Brachial Plexus Block. A Randomized Controlled Double Blinded Dose Ranging Study Unknown status NCT03043495 Phase 4 Dexamethasone
6 Comparison of Analgesic Efficacy of Two Different Doses of Dexmedetomidine as Adjuncts to Lidocaine for Intravenous Regional Anesthesia: Randomized Clinical Trial. Unknown status NCT03399474 Phase 4 Dexmedetomidine Injection 0.25 ug/kg;Lidocaine;Nalbuphine;Paracetamol;Diclofenac sodium (Voltaren®);Dexmedetomidine Injection 0.5ug/kg
7 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
8 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Completed NCT03067285 Phase 4 ELV/COBI/FTC/TAF;DTG/3TC/ABC + ELV/COBI/FTC/TAF
9 Thermal Quantitative Sensory Testing as a Method to Semi-quantitatively Assess the Neurosensory Effects of 3 Local Anesthetic Solutions in an Interscalene Block Completed NCT02271867 Phase 4
10 A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment Completed NCT01675531 Phase 4 Targin
11 Double Blinded Randomized Controlled Study Evaluating the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block in Patients Undergoing Ambulatory Shoulder Surgery Completed NCT02653144 Phase 4 Ropivacaine;Dexmedetomidine;Dexamethasone
12 Phase IV Study of Cognitive and Behavioral Effects of Lacosamide as Adjunctive Therapy in Patients With Partial Epilepsy Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
13 Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression Completed NCT00306397 Phase 4 Rapamycin
14 Effects of Peri-neural Dexmedetomidine on the Pharmacodynamic Profile of Bupivacaine-induced Adductor Canal Block in Patients Undergoing Arthroscopic Medial Meniscectomy Completed NCT03030950 Phase 4 Dexmedetomidine;Normal saline
15 Interventional Multicentre Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation Completed NCT03076151 Phase 4 Tacrolimus monohydrate (ADOPORT®)
16 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
17 Taste and Smell Changes in Testicular Cancer Patients Treated With Cisplatin Based Chemotherapy Completed NCT01641172 Phase 4
18 A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy. Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
19 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
20 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment. Completed NCT01372904 Phase 4 Dexamethasone Phosphate
21 Steroid Free Immunosuppression in Liver Transplantation Completed NCT00296244 Phase 4 Steroids;Basiliximab;Tacrolimus;Enteric-coated Mycophenolic acid (EC-MPA)
22 Adductor Canal Block: Single Injection vs Catheter for Pain Management of Total Knee Arthroplasty - A Randomized, Unblinded, Non-Inferiority Trial Completed NCT02798835 Phase 4 Adductor canal block;Adductor canal block with dexamethasone;Adductor canal catheter;Bupivacaine;Fentanyl;Ropivacaine 0.5% Injectable Solution;Dexamethasone
23 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
24 Phase IV, Open Label, Randomized, Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir Alafenamide/Emtricitabine/Darunavir/Cobicistat Recruiting NCT03685500 Phase 4 Symtuza® (TAF/FTC/DRV/c);ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)
25 The Effect of Conversion to Once-Daily Envarsus® on the Neurologic Toxicity Burden in Liver Transplant Recipients Recruiting NCT03823768 Phase 4 Envarsus;Tacrolimus Immediate release
26 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
27 Study on Efficacy and Safety of Huangqi Guizhi Wuwu Decoction Treatment for Oxaliplatin Induced Peripheral Neurotoxicity: a Protocol for a Randomized, Controlled, Double-blind, Multi-center Trial Recruiting NCT04261920 Phase 4 Huangqi Guizhi Wuwu decoction
28 MARaviroc-based Treatment Switch in HIV-positive Patients With HAND: Consequences of Reducing Antiretroviral-associated Neurotoxicity Recruiting NCT03163277 Phase 4 emtricitabine, darunavir/cobicistat, maraviroc
29 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial Recruiting NCT02334722 Phase 4 Levetiracetam extended release
30 Impact of Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block on Postoperative Delirium and Long-term Oucomes in Elderly Patients After Single Knee Arthroplasty Recruiting NCT03629483 Phase 4 Dexmedetomidine;Placebo
31 Comparison of Ropivacaine With or Without Fentanyl in Spinal Anaesthesia for Lower Limb Surgeries Recruiting NCT04199013 Phase 4 Ropivacaine 0.75% Injectable Solution;Fentanyl Citrate
32 Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA Recruiting NCT02213068 Phase 4 belatacept;Tacrolimus;MPA
33 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Active, not recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
34 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
35 Comparison of Periosteal and Subcutaneous Infusions of Articaine and Bupivacaine in Treatment of Acute Pain After Sternotomy Suspended NCT01536717 Phase 4 Articaine hydrochloride 2% solution;Sodium Chloride
36 Pilot Study of L-Carnitine Supplementation in the Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Metastatic Breast Cancer Terminated NCT00754767 Phase 4 L-carnitine L-tartrate
37 A Prospective Randomized Trial of Prednisone and Tacrolimus Versus Prednisone, Tacrolimus and Mycophenolate Mofetil in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 mycophenolate mofetil
38 CONCEPT - Phase IV, Randomized, Prospective, Multicenter Comparison of Intermittent Schedule of Oxaliplatin Combined With FOLFOX/Bevacizumab vs Conventional Mode of Administration of FOLFOX/Bevacizumab + Neuroprophylaxis With Calcium/Magnesium for Optimization of First-Line Therapy of Metastatic Colorectal Cancer Terminated NCT00129870 Phase 4 oxaliplatin
39 Pain Management After Total Shoulder Arthroplasty: Continuous Interscalene Block Versus Local Tissue Infiltration With Liposomal Bupivacaine Terminated NCT03219983 Phase 4 Ropivacaine;liposomal bupivacaine
40 The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Gastric Cancer Unknown status NCT02024438 Phase 3 monosialotetrahexosylganglioside Sodium
41 The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Colorectal Cancer Unknown status NCT02024412 Phase 3 monosialotetrahexosylganglioside Sodium
42 A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by First-line Chemotherapy Contained Cisplatin in Non-small Cell Lung Cancer Patients. Unknown status NCT01882621 Phase 3 Monosialoganglioside(GM1);normal saline
43 Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study Unknown status NCT02084355 Phase 3 oral oxycodone;oral hydromorphone;fentanyl patch
44 Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma Unknown status NCT02289547 Phase 3 Capecitabine
45 The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients. Randomized Trial Unknown status NCT02024191 Phase 3
46 Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study Unknown status NCT00660842 Phase 3 paclitaxel;carboplatin;paclitaxel
47 A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
48 Phase III Italian Multicenter Study Comparing the Combination of 5-fluorouracil/Folinic Acid, Oxaliplatin and Irinotecan (Folfoxiri) Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer Unknown status NCT02355119 Phase 3 FOLFOXIRI;Gemcitabine
49 CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study Unknown status NCT00054184 Phase 3 docetaxel;paclitaxel poliglumex
50 Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication Unknown status NCT02138864 Phase 3

Search NIH Clinical Center for Toxic Encephalopathy

Cochrane evidence based reviews: neurotoxicity syndromes

Genetic Tests for Toxic Encephalopathy

Anatomical Context for Toxic Encephalopathy

MalaCards organs/tissues related to Toxic Encephalopathy:

40
Brain, Breast, Lung, Liver, T Cells, B Cells, Colon

Publications for Toxic Encephalopathy

Articles related to Toxic Encephalopathy:

(show top 50) (show all 419)
# Title Authors PMID Year
1
[Clinical analysis of 15 cases of acute glufosinate poisoning]. 61
32536077 2020
2
Toxic Leukoencephalopathy: An unusual Presentation by 5-Fluorouracil Infusion. 61
32476656 2020
3
Specific EEG Encephalopathy Pattern in SARS-CoV-2 Patients. 61
32443834 2020
4
Wernicke encephalopathy associated with hyperemesis gravidarum. 61
31784394 2020
5
Two case reports of novel syndrome of bizarre performance of gastrointestinal endoscopy due to toxic encephalopathy of endoscopists among 181767 endoscopies in a 13-year-university hospital review: Endoscopists, first do no harm! 61
32206008 2020
6
Short-Course Self-Medication of Metronidazole Leading to Acute Toxic Encephalopathy and Ataxia. 61
31736605 2019
7
[Analysis of 18 cases of toxic encephalopathy caused by occupational acute 1, 2-dichloroethane poisoning]. 61
31726511 2019
8
Diagnosing solvent-induced chronic toxic encephalopathy: the effect of underperformance in neuropsychological testing. 61
31082289 2019
9
Roles of neuroimage in toxic encephalopathy induced by 1, 2-Dichloroethane. 61
31319235 2019
10
Cephalosporin-related neurotoxicity: Metabolic encephalopathy or non-convulsive status epilepticus? 61
31201049 2019
11
Neurologic Acyclovir Toxicity in the Absence of Kidney Injury. 61
31171414 2019
12
Baclofen Neurotoxicity: A Metabolic Encephalopathy Susceptible to Exacerbation by Benzodiazepine Therapy. 61
30688773 2019
13
Methadone-induced Toxic Encephalopathy In Pediatric Patients: Two Case Reports. 61
31558953 2019
14
The clinical and pathological features of toxic encephalopathy caused by occupational 1,2-dichloroethane exposure. 61
31027082 2019
15
Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment. 61
29121830 2019
16
Toxic Encephalopathy After Relapsed Indolent Non-Hodgkin's Lymphoma Following Abrupt Discontinuation of Idelalisib (ZYDELIG®). 61
31016071 2019
17
Successful treatment of a patient with severe thallium poisoning in a coma using Prussian blue and plasma exchange: A case report. 61
30813198 2019
18
[Characteristics of clinical, Magnetic Resonance Imaging and electroencephalogram after trimethyltin chloride poisoning]. 61
30929356 2019
19
Epileptic seizures and occupational exposure to solvents: a cases series. 61
30794249 2019
20
Human adenovirus type 7 infection causes a more severe disease than type 3. 61
30626350 2019
21
Therapeutic Potential of Citronella Essential Oil: A Review. 61
30019646 2019
22
Acute toxic encephalopathy induced by occupational exposure to 1,2-dichloropropane. 61
29973469 2018
23
1,2-Dichloroethane-induced hepatotoxicity and apoptosis by inhibition of ERK 1/2 pathways. 61
29852074 2018
24
Quantification of hypoglycin A and methylenecyclopropylglycine in human plasma by HPLC-MS/MS. 61
30056267 2018
25
Imaging the Unconscious "Found Down" Patient in the Emergency Department. 61
30007754 2018
26
Cuban Epidemic Neuropathy: Insights into the Toxic-Nutritional Hypothesis through International Collaboration. 61
29773773 2018
27
An easily overlooked cause of toxic encephalopathy: methylene blue in a patient on an SSRI. 61
28748330 2018
28
An aggravated return-to-work case of organic solvent induced chronic toxic encephalopathy. 61
29719722 2018
29
[M'khinza-related intoxication: about two observations]. 61
30918546 2018
30
A Novel Mutation of Beta-ketothiolase Deficiency: The First Report from Iran and Review of Literature. 61
30026775 2018
31
REYE (RAY'S) SYNDROME: A PROBLEM EVERYONE SHOULD REMEMBER. 61
29227269 2017
32
Survival in Out-of-hospital Rapid Sequence Intubation of Non-Traumatic Brain Pathologies. 61
28622071 2017
33
Mercury poisoning through intravenous administration: Two case reports with literature review. 61
29145289 2017
34
Gardnerella vaginalis bacteremia associated with severe acute encephalopathy in a young female patient. 61
28546029 2017
35
[Clinical effect of electroencephalographic biofeedback therapy in treatment of memory disorders in patients with acute severe toxic encephalopathy]. 61
29294552 2017
36
Subcortical brain atrophy in Gulf War Illness. 61
28634886 2017
37
Routine fruit washing to prevent acute toxic encephalopathy. 61
28807178 2017
38
Routine fruit washing to prevent acute toxic encephalopathy - Authors' reply. 61
28807179 2017
39
[An investigation of an accident of occupational acute hydrogen sulfide poisoning]. 61
29081104 2017
40
Association of acute toxic encephalopathy with litchi consumption in an outbreak in Muzaffarpur, India, 2014: a case-control study. 61
28153514 2017
41
[ACTION OF L-CARNITINE, CORVITIN AND THEIR COMBINATION ON FUNCTIONAL STATE OF LIVER IN EXPERIMENTAL MODEL OF REYE SYNDROME IN RATS]. 61
28452736 2017
42
Myoclonic seizure prior to diagnosis of chronic toxic encephalopathy: a case report. 61
28173825 2017
43
Early Non-invasive Detection of Acute 1,2-Dichloroethane-induced Toxic Encephalopathy in Rats. 61
27815462 2016
44
Emergency treatment and nursing of children with severe pneumonia complicated by heart failure and respiratory failure: 10 case reports. 61
27698703 2016
45
Poster 349 Toxic Encephalopathy and Rash Resulting from Paradichlorobenzene Inhalation: A Case Report. 61
27673102 2016
46
Marchiafava-Bignami disease in chronic alcoholic patient. 61
27594956 2016
47
[Toxic encephalopathy caused by liquefied gas exposure: Report of one case]. 61
27905657 2016
48
The effect of hemoperfusion on patients with toxic encephalopathy induced by silkworm chrysalis ingestion. 61
26610794 2016
49
Odorless inhalant toxic encephalopathy in developing countries household: Gas geyser syndrome. 61
27114653 2016
50
[The role of smoking and metabolic enzyme polymorphisms in the organic solvent induced chronic encephalopathy]. 61
27220440 2016

Variations for Toxic Encephalopathy

Expression for Toxic Encephalopathy

Search GEO for disease gene expression data for Toxic Encephalopathy.

Pathways for Toxic Encephalopathy

Pathways related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1 12.68 TNF NGF IL1B CASP3 BDNF
2
Show member pathways
12.62 TNF TH SNCA SLC6A3 PSEN1 IL1B
3 12.42 TH SNCA PSEN1 NGF GRIN2B APP
4 12.04 NGF GRIN2B CASP3 BDNF
5 12.01 TNF IL1B HMOX1 GSTM1
6 11.94 TNF TH NGF IL1B CASP3 BDNF
7
Show member pathways
11.9 TH SLC6A3 GRIN2B BDNF
8 11.8 TNF IL1B CASP3 BDNF AIF1
9
Show member pathways
11.7 GSTM1 EPHX1 ABCG2
10 11.7 TH SNCA SLC6A3 CASP3
11 11.67 TNF IL1B CASP3
12
Show member pathways
11.67 TNF NGF BDNF APP
13 11.63 TH NGF BDNF ABCG2
14 11.59 HMOX1 ABCG2 ABCB1
15 11.57 TNF IL1B HMOX1
16 11.52 TNF IL1B CASP3
17 11.4 TNF SNCA PSEN1 MIR9-1 IL1B GRIN2B
18
Show member pathways
11.37 PSEN1 NGF CASP3 BDNF APP
19
Show member pathways
11.3 TNF TH SLC6A3 IL1B
20 11.28 TNF IL1B HMOX1
21 11.23 TH SNCA SLC6A3
22 11.22 TNF NGF CASP3
23 11.18 TNF IL1B ABCG2
24 11.03 HMOX1 EPHX1 ABCG2
25 10.36 GSTM1 EPHX1

GO Terms for Toxic Encephalopathy

Cellular components related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.98 TH SNCA PSEN1 HMOX1 GRIN2B APP
2 cytoplasmic vesicle GO:0031410 9.95 TH PSEN1 NGF IL1B BDNF APP
3 neuron projection GO:0043005 9.91 TH SLC6A3 PSEN1 GRIN2B APP
4 neuronal cell body GO:0043025 9.85 TH SNCA SLC6A3 PSEN1 CASP3
5 cell surface GO:0009986 9.85 TNF SLC6A3 PSEN1 GRIN2B APP ABCB1
6 perinuclear region of cytoplasm GO:0048471 9.8 TH SNCA PSEN1 HMOX1 BDNF APP
7 rough endoplasmic reticulum GO:0005791 9.67 SNCA PSEN1 APP
8 membrane raft GO:0045121 9.63 TNF SLC6A3 PSEN1 CASP3 APP ABCG2
9 ciliary rootlet GO:0035253 9.52 PSEN1 APP
10 smooth endoplasmic reticulum GO:0005790 9.5 TH PSEN1 APP
11 axon GO:0030424 9.5 TH SNCA SLC6A3 PSEN1 NGF BDNF
12 external side of apical plasma membrane GO:0098591 9.4 ABCG2 ABCB1
13 synaptic vesicle GO:0008021 9.1 TH SNCA PSEN1 NGF BDNF APP

Biological processes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.14 SNCA PSEN1 IL1B HMOX1 CASP3 APP
2 positive regulation of gene expression GO:0010628 10.12 TNF PSEN1 NGF IL1B APP
3 negative regulation of cell proliferation GO:0008285 10.1 NGF MIR9-1 IL1B HMOX1 APP
4 negative regulation of apoptotic process GO:0043066 10.06 SNCA PSEN1 NGF CASP3 BDNF AIF1
5 positive regulation of apoptotic process GO:0043065 9.99 TNF SNCA PSEN1 NGF HMOX1 CASP3
6 response to lipopolysaccharide GO:0032496 9.96 TH SNCA IL1B CASP3
7 response to drug GO:0042493 9.93 TH SNCA SLC6A3 CASP3 BDNF ABCB1
8 positive regulation of JNK cascade GO:0046330 9.9 TNF IL1B APP
9 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.9 TNF SNCA NGF
10 positive regulation of protein phosphorylation GO:0001934 9.89 TNF PSEN1 IL1B APP AIF1
11 cellular response to organic cyclic compound GO:0071407 9.88 TNF IL1B CASP3
12 response to organic cyclic compound GO:0014070 9.88 TH SLC6A3 EPHX1 CASP3
13 response to glucocorticoid GO:0051384 9.87 TNF CASP3 AIF1
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF IL1B APP
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF HMOX1 AIF1
16 synapse organization GO:0050808 9.85 SNCA PSEN1 APP
17 memory GO:0007613 9.85 TH PSEN1 NGF BDNF
18 regulation of synaptic plasticity GO:0048167 9.84 PSEN1 GRIN2B BDNF
19 cognition GO:0050890 9.83 TNF TH APP
20 negative regulation of neuron apoptotic process GO:0043524 9.83 SNCA PSEN1 NGF HMOX1 BDNF
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 TNF IL1B AIF1
22 positive regulation of interleukin-6 secretion GO:2000778 9.81 TNF IL1B AIF1
23 neuron apoptotic process GO:0051402 9.81 PSEN1 CASP3 APP
24 response to interleukin-1 GO:0070555 9.78 SNCA IL1B APP
25 negative regulation of apoptotic signaling pathway GO:2001234 9.74 TNF PSEN1 BDNF
26 neuron projection maintenance GO:1990535 9.72 PSEN1 APP
27 transepithelial transport GO:0070633 9.72 ABCG2 ABCB1
28 response to salt stress GO:0009651 9.71 TNF TH
29 modulation of age-related behavioral decline GO:0090647 9.71 PSEN1 APP
30 cellular response to nicotine GO:0071316 9.71 TNF TH
31 cellular response to manganese ion GO:0071287 9.71 TH APP
32 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.71 TNF APP
33 positive regulation of amyloid-beta formation GO:1902004 9.71 TNF CASP3 APP
34 hyaloid vascular plexus regression GO:1990384 9.7 TH SLC6A3
35 neurotrophin TRK receptor signaling pathway GO:0048011 9.7 NGF CASP3 BDNF
36 regulation of establishment of endothelial barrier GO:1903140 9.69 TNF IL1B
37 export across plasma membrane GO:0140115 9.69 ABCG2 ABCB1
38 positive regulation of collateral sprouting GO:0048672 9.69 NGF BDNF
39 mating behavior GO:0007617 9.68 TH APP
40 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.67 PSEN1 APP
41 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF AIF1
42 response to nicotine GO:0035094 9.67 TH SLC6A3 HMOX1 CASP3
43 dopamine uptake involved in synaptic transmission GO:0051583 9.65 SNCA SLC6A3
44 positive regulation of fever generation GO:0031622 9.65 TNF IL1B
45 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.65 TNF IL1B APP
46 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.65 TNF SNCA NGF BDNF APP
47 positive regulation of amyloid fibril formation GO:1905908 9.63 PSEN1 APP
48 sequestering of triglyceride GO:0030730 9.62 TNF IL1B
49 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.62 PSEN1 APP
50 microglial cell activation GO:0001774 9.62 TNF SNCA APP AIF1

Molecular functions related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.55 TH SNCA HMOX1 GSTM1 APP
2 growth factor receptor binding GO:0070851 9.26 PSEN1 APP
3 nerve growth factor receptor binding GO:0005163 8.96 NGF BDNF
4 xenobiotic transmembrane transporting ATPase activity GO:0008559 8.62 ABCG2 ABCB1

Sources for Toxic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....